Not available
Quote | Codexis Inc. (NASDAQ:CDXS)
Last: | $3.68 |
---|---|
Change Percent: | 0.0% |
Open: | $3.55 |
Close: | $3.68 |
High: | $3.71 |
Low: | $3.4 |
Volume: | 634,986 |
Last Trade Date Time: | 07/22/2024 03:00:00 am |
News | Codexis Inc. (NASDAQ:CDXS)
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the second quarter of 2024 on Thursday, August 8, 2024, following the close of market. Codexis management will ...
2024-07-01 17:28:05 ET More on Codexis Codexis, Inc. (CDXS) Q1 2024 Earnings Call Transcript Codexis, Inc. 2024 Q1 - Results - Earnings Call Presentation Codexis GAAP EPS of -$0.16 beats by $0.02, revenue of $17.1M beats by $3.8M Codexis Q1 2024 Earnings Prev...
Message Board Posts | Codexis Inc. (NASDAQ:CDXS)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $CDXS News Article - Codexis Announces Appointment of Sri Ryali as Chief Financial Offi | whytestocks | investorshangout | 01/23/2023 9:15:51 PM |
whytestocks: $CDXS News Article - Codexis Announces the Publication of Research Demonstrating Proof | whytestocks | investorshangout | 06/17/2022 2:10:54 PM |
whytestocks: $CDXS News Article - Codexis Presents Pre-Clinical Data Highlighting its Programs in Ho | whytestocks | investorshangout | 11/22/2021 4:35:50 PM |
whytestocks: $CDXS News Article - Codexis Inc (CDXS) Q3 2021 Earnings Call Transcript | whytestocks | investorshangout | 11/05/2021 1:55:49 PM |
Cathie Wood can't be the only one to | jerseyboy | investorshub | 03/21/2021 2:46:33 PM |
News, Short Squeeze, Breakout and More Instantly...
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the second quarter of 2024 on Thursday, August 8, 2024, following the close of market. Codexis management will ...
REDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk Therapeutics for the Company’s investigational Fabry and Pompe disease compounds. Under...
2024-05-30 07:30:04 ET Cantor Fitzgerald analyst issues OVERWEIGHT recommendation for CDXS on May 30, 2024 06:15AM ET. CDXS was trading at $3.19 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy rec...